[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 472
1. Dempsey MF, Condon BR, Hadley DM: Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol; 2005 Apr;26(4):770-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?
  • BACKGROUND AND PURPOSE: Tumor "size" is used internationally as a surrogate marker for overall survival when following current response assessment protocols (World Health Organization and Response Evaluation Criteria in Solid Tumors).
  • With little evidence of a relationship between tumor "size" and survival in intrinsic brain tumors, this study was undertaken to investigate the predictive value of MR imaging-defined tumor size for survival in patients with recurrent malignant glioma and to compare the different measures of tumor size used in these current response assessment protocols.
  • METHODS: Volumetric, bidimensional, and unidimensional measurements of tumor size were made using baseline contrast-enhanced T1-weighted images of 70 patients with recurrent malignant glioma receiving intravenous chemotherapy.
  • Cox's proportional hazards model was used to investigate the prognostic importance of tumor size using survival as the end point.
  • RESULTS: Only the volumetric measurement of tumor size was found to be predictive of survival in recurrent malignant glioma on both univariate and multivariate analysis.
  • Furthermore, analysis demonstrated that the unidimensional and bidimensional measures of tumor were not comparable with the more accurate and direct volumetric measurement.
  • CONCLUSION: Indirect unidimensional and bidimensional measurement techniques do not have a significant association with overall survival or adequately assess tumor size in recurrent malignant glioma.
  • These findings have serious implications about the validity of using current response assessment protocols in therapy trials for recurrent malignant glioma.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814919.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol; 2007 Jun 20;25(18):2601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.
  • Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially.
  • PATIENTS AND METHODS: Between 1995 and 2002, 333 adults with recurrent gliomas were enrolled onto 10 phase I or II trials of systemic or local therapy.
  • The studies had similar inclusion criteria and were conducted within the New Approaches to Brain Tumor Therapy CNS Consortium.
  • RESULTS: Factors associated with an increased risk of death were increased age, lower Karnofsky performance score (KPS), initial and on-study histologies of glioblastoma multiforme (GBM), corticosteroid use, shorter time from original diagnosis to recurrence, and tumor outside frontal lobe.
  • Median survival time was poorest in non-GBM patients with KPS less than 80 or GBM patients, age 50 years, corticosteroid use (4.4 months; 95% CI, 3.6 to 5.4 months); median survival was best in patients with initial histology other than GBM with KPS 80 and tumor confined to the frontal lobe (25.7 months; 95% CI, 18.7 to 52.5), and was 7.0 months (95% CI, 6.2 to 8.0 months) for all patients.
  • CONCLUSION: Initial histology, age, KPS, and corticosteroid use are prognostic for survival in recurrent glioma patients.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3260-6 [11432894.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):29-33 [11302251.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:150-7 [10549485.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5174-81 [16951236.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:123-7 [9073058.001]
  • [Cites] J Clin Epidemiol. 1995 May;48(5):675-89 [7730923.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):615-9 [14628127.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):958-66 [15509513.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):38-44 [6321671.001]
  • [Cites] Acta Oncol. 1989;28(1):51-5 [2539846.001]
  • [CommentIn] J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4 [22215743.001]
  • (PMID = 17577040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / CA62475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS507874; NLM/ PMC4118746
  •  go-up   go-down


3. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol; 2009 Jan;91(2):183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
  • This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic glioma when treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC).
  • Treatment with poly-ICLC continued until tumor progression.
  • Ten were ineligible after central review of pathology.
  • Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 [18262679.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Immunology. 2008 Aug;124(4):480-8 [18248388.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Interferon Res. 1982;2(1):1-4 [6180095.001]
  • [Cites] Tex Rep Biol Med. 1981-1982;41:653-62 [6189230.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1058-65 [3155990.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2483-91 [2411797.001]
  • [Cites] J Biol Response Mod. 1985 Oct;4(5):475-80 [2416882.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):640-9 [2418162.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):664-8 [2418164.001]
  • [Cites] Gynecol Oncol. 1986 Jul;24(3):359-61 [3721308.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1341-2 [3768878.001]
  • [Cites] J Urol. 1987 Feb;137(2):202-6 [3806804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3005-10 [1591717.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):120-6 [1318961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):75-83 [7721642.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Methods Mol Biol. 2007;383:277-301 [18217692.001]
  • (PMID = 18850068.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062421-08; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; 9004-32-4 / Carboxymethylcellulose Sodium
  • [Other-IDs] NLM/ NIHMS291833; NLM/ PMC3104130
  •  go-up   go-down


Advertisement
4. Al Sayyari A, Buckley R, McHenery C, Pannek K, Coulthard A, Rose S: Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy. AJNR Am J Neuroradiol; 2010 Jun;31(6):1049-54
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy.
  • BACKGROUND AND PURPOSE: The accurate delineation of tumor recurrence presents a significant problem in neuro-oncology.
  • Our aim was to improve the identification of brain tumor recurrence from chemoradiation injury by using CE-SWI, a technique that provides improved visualization of the heterogeneous patterns of brain tumor pathology, to guide the analysis of ADC measures within the peritumoral territory.
  • RESULTS: Analysis of the serial data revealed that patients with a diagnosis of tumor recurrence had significantly reduced ADC measures within the enhancement volume delineated on CE-SWI.
  • CONCLUSIONS: The findings of an increase in enhancement volume delineated on serial CE-SWI maps, along with a concomitant reduction in ADC within this volume for patients with recurrent tumor, provide support for such an approach to be used to assist in follow-up patient management strategies.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / pathology. Astrocytoma / radiotherapy. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110377.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000077
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


6. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W: Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med; 2010 Oct;51(10):1532-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
  • 6-(18)F-fluoro-l-dopa ((18)F-FDOPA) measured with PET as a biomarker of amino acid uptake has been investigated in brain tumor imaging.
  • The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas.
  • METHODS: Fifty-nine patients (40 men, 19 women; mean age ± SD, 44.4 ± 12.3 y) with newly diagnosed (n = 22) or recurrent (n = 37) gliomas underwent (18)F-FDOPA PET perioperatively.
  • Tumor tissue was obtained by resection or biopsy in all patients.
  • The tumor grade and Ki-67 proliferation index were obtained by standard pathology assays.
  • Tumor (18)F-FDOPA uptake was quantified by determining various standardized uptake value (SUV) parameters (mean SUV, maximum SUV [SUVmax], mean values of voxels with top 20% SUVs, and tumor-to-normal-brain tissue ratios) that were then correlated with histopathologic grade and Ki-67 proliferation index.
  • RESULTS: Fifty-nine lesions in 59 patients were analyzed. (18)F-FDOPA uptake was significantly higher in high-grade than in low-grade tumors for newly diagnosed tumors (SUVmax, 4.22 ± 1.30 vs. 2.34 ± 1.35, P = 0.005) but not for recurrent tumors that had gone through treatment previously (SUVmax, 3.36 ± 1.26 vs. 2.67 ± 1.18, P = 0.22).
  • An SUVmax threshold of 2.72 differentiated low-grade from high-grade tumors, with a sensitivity and specificity of 85% and 89%, respectively, using receiver-operating-characteristic curve analysis (area under the curve, 0.86). (18)F-FDOPA PET uptake correlated significantly with Ki-67 tumor proliferation index in newly diagnosed tumors (r = 0.66, P = 0.001) but not in recurrent tumors (r = 0.14, P = 0.41).
  • CONCLUSION: (18)F-FDOPA uptake is significantly higher in high-grade than in low-grade tumors in newly diagnosed but not recurrent tumors that had been treated previously.
  • A significant correlation between (18)F-FDOPA uptake and tumor proliferation in newly diagnosed tumors was observed, whereas this correlation was not identified for recurrent tumors.
  • Thus, (18)F-FDOPA PET might serve as a noninvasive marker of tumor grading and might provide a useful surrogate of tumor proliferative activity in newly diagnosed gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Dihydroxyphenylalanine / analogs & derivatives. Glioma / metabolism. Glioma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847166.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 128812-04-4 / 2,6-difluoro-3,4-dihydroxyphenylalanine; 63-84-3 / Dihydroxyphenylalanine
  •  go-up   go-down


7. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors.
  • Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


8. Seo YS, Chung TW, Kim IY, Bom HS, Min JJ: Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET. Clin Nucl Med; 2008 Jan;33(1):32-3
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET.
  • A 43-year-old man with a history of lung cancer, brain metastasis, and gamma knife radiosurgery underwent FDG PET/CT to differentiate recurrence from radiation necrosis.
  • Basal PET/CT scan showed equivocal uptake in the margin of necrotic tumor.
  • Proton magnetic resonance spectroscopy (1H-MRS) showed increased Cho/Cr ratio (1.7), which was consistent with tumor recurrence.
  • The patient underwent whole brain radiotherapy thereafter.
  • It is implicated that hyperglycemia-induced reduction of glucose uptake in recurrent brain tumors was less than in a normal brain, resulting in higher tumor-to-gray matter ratio.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Gadolinium DTPA. Glucose. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097254.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


9. Sundgren PC, Fan X, Weybright P, Welsh RC, Carlos RC, Petrou M, McKeever PE, Chenevert TL: Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging; 2006 Nov;24(9):1131-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions.
  • BACKGROUND AND PURPOSE: The purpose of this study was to assess the use of diffusion tensor imaging (DTI) in the evaluation of new contrast-enhancing lesions and perilesional edema in patients previously treated for brain neoplasm in the differentiation of recurrent neoplasm from treatment-related injury.
  • METHODS: Twenty-eight patients with new contrast-enhancing lesions and perilesional edema at the site of previously treated brain neoplasms were retrospectively reviewed.
  • Mean apparent diffusion coefficient (ADC), fractional anisotropy (FA) and eigenvalue indices (lambda( parallel) and lambda( perpendicular)) and their ratios relative to the contralateral side were compared in patients with recurrent neoplasm versus patients with radiation injury, as established by histological examination or by clinical course, including long-term imaging studies and magnetic resonance spectroscopy.
  • The ADC ratios in the white matter tracts in perilesional edema trended higher (P=.09) in treatment-related injury than in recurrent neoplasm (mean+/-S.D.
  • CONCLUSION: The assessment of diffusion properties, especially ADC values and ADC ratios, in contrast-enhancing lesions, perilesional edema and NAWM adjacent to the edema in the follow-up of new contrast-enhancing lesions at the site of previously treated brain neoplasms may add to the information obtained by other imaging techniques in the differentiation of radiation injury from tumor recurrence.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071335.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / 1 K07 CA108664 01A1; United States / NCI NIH HHS / CA / CA 85878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


10. Amthauer H, Wurm R, Kuczer D, Ruf J, Michel R, Eisenacher J, Stockhammer F, Denecke T, Felix R, Plotkin M: Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor. Clin Nucl Med; 2006 Apr;31(4):189-92
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor.
  • PURPOSE: The aim of the study was to investigate the impact of MR/SPECT image fusion on the interpretation of I-123 iodo-methyl-tyrosine (IMT) SPECT examinations in patients with pretreated brain tumors.
  • MATERIAL AND METHODS: In this retrospective study, 45 consecutive patients with suspected recurrent/residual gliomas (n = 41) or cerebral metastases (n = 4) were included.
  • SPECT studies were performed using a triple-head gamma-camera system 10 minutes after injection of 300 to 370 MBq (8.1-10 mCi) I-123 IMT.
  • Tumor localization and extent were evaluated and correlated with histopathology or clinical follow up, including MR imaging.
  • RESULTS: In 10 of 45 (22%) patients, image fusion had a significant impact on the interpretation of scans: 5 suspected SPECT findings were correctly classified as physiological or therapy-related; in another 5 patients, image fusion added relevant clinical information on tumor extent (infiltration of the contralateral hemisphere n = 3, infiltration of the brain stem n = 2).
  • [MeSH-major] Brain Neoplasms / pathology. Iodine Radioisotopes. Magnetic Resonance Imaging. Methyltyrosines. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550008.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 14684-02-7 / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


11. Skvortsova TIu, Brodskaia ZL, Rudas MS, Mozhaev SV, Gurchin AF, Medvedev SV: [Positron emission tomography in the diagnosis of recurrent growth of brain tumors]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Apr-Jun;(2):3-7; discussion 7
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography in the diagnosis of recurrent growth of brain tumors].
  • The authors analyzed the results of 11C-methionine positron emission tomography (PET) in 101 patients with suspected recurrent brain tumor.
  • The increased 11C-methionine uptake in the initial tumor area is considered to be a crucial PET evidence of a recurrent tumor.
  • On the other hand, brain tissue histological changes associated with surgery, radiation, and chemotherapy were characterized by the low uptake of the tracer.
  • The sensitivity and specificity of PET scanning in detecting tumor recurrence were found to be 95.8 and 96.5%, respectively.
  • 11C-methionine PET is proposed as a reliable technique for early differentiating between a recurrent brain tumor and treatment-induced nonneoplastic changes.
  • [MeSH-major] Brain Neoplasms / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiation effects. Carbon Radioisotopes. Child. Child, Preschool. Female. Glioma / diagnosis. Glioma / pathology. Humans. Male. Methionine. Middle Aged. Necrosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078626.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


12. Shen S, Nabors LB, Raizer JJ, Fiveash JB, Spies S, Costello R, O'Neill AM: Dosimetry study of a phase II multiple-dose intracavitary administration of <sup>131</sup>I-TM601 in adult patients with recurrent high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetry study of a phase II multiple-dose intracavitary administration of <sup>131</sup>I-TM601 in adult patients with recurrent high-grade glioma.
  • Dose escalation of external beam radiotherapy or brachytherapy is limited by normal brain radionecrosis.
  • Radiolabeled targeting molecules can deliver localized radiation to tumor and reduce normal brain radionecrosis.
  • TM601, or synthetic Chlorotoxin, is a peptide derived from scorpion venom that specifically binds to tumor cells.
  • Here we report dosimetry results of an imaging sub-study of a phase II trial, in which weekly doses of <sup>131</sup>I-TM601 were infused into surgically created tumor resection cavities for 3 or 6 weeks.
  • For each imaging study, 5 sequential SPECT images (1-168 hour) were registered with MRI to determine the <sup>131</sup>I-TM601 radiation dose to the 2-cm tumor cavity margin.
  • Median tumor cavity volume was 11.4 mL, and ranged 5.2 - 35.5 mL.
  • These results support the multi-dose fractionation scheme for <sup>131</sup>I-TM601 to minimize normal tissue toxicity, including radiation necrosis, and extend continuous irradiation to clinical or sub-clinical residual tumor cells after surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • METHODS: Twenty-two patients aged 24 to 60 years with recurrent AO were treated.
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • CONCLUSIONS: Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent 1p19q codeleted alkylator-refractory AO.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


14. Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE: Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res; 2008 Feb 15;14(4):1124-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
  • PURPOSE: VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors.
  • Central imaging review confirmed that three patients had stable disease for a median of 45 weeks (range, 37-61+) after therapy.
  • CONCLUSIONS: The recommended dose of VNP40101M for phase II studies in children with brain tumors is 45 mg/m(2)/d in moderately pretreated and 30 mg/m(2)/d in heavily pretreated patients when administered for 5 consecutive days every 6 weeks.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Hydrazines / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Child, Preschool. Humans. Infant. Maximum Tolerated Dose

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281546.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00188; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  •  go-up   go-down


15. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol; 2009 Mar 10;27(8):1268-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
  • These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
  • Tumor specimens obtained at first surgery were investigated for EGFR expression; EGFRvIII mutants; EGFR amplification; EGFR mutations in exons 18, 19, and 21; and pAkt.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. PTEN Phosphohydrolase / analysis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Anticancer Drugs. 2008 Feb;19(2):209-16 [18176118.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] Clin Lung Cancer. 2006 Dec;8 Suppl 1:S7-14 [17239291.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Science. 2007 Oct 12;318(5848):287-90 [17872411.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):159-63 [11302336.001]
  • (PMID = 19204207.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / epidermal growth factor receptor VIII; 7GR28W0FJI / Dacarbazine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; U68WG3173Y / Carmustine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2667826
  •  go-up   go-down


16. Stockhammer F, Misch M, Koch A, Czabanka M, Plotkin M, Blechschmidt C, Tuettenberg J, Vajkoczy P: Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol; 2010 Dec;100(3):407-15
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
  • Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months.
  • We report our experience with this procedure in recurrent glioblastomas after standard treatment.
  • From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m(2) twice daily and 200 mg celecoxib.
  • Before therapy the recurrent tumor was resected in 19 of 28 patients.
  • Tumor progression was defined by the Macdonald criteria on MRI every 8-12 weeks or by clinical deterioration.
  • A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test).
  • Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Celecoxib. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Disease-Free Survival. Female. Fluorine Radioisotopes. Follow-Up Studies. Humans. Male. Methylation / drug effects. Middle Aged. Positron-Emission Tomography / methods. Retrospective Studies. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Tyrosine / analogs & derivatives

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446016.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclooxygenase 2 Inhibitors; 0 / Fluorine Radioisotopes; 0 / O-(3-fluoropropyl)tyrosine; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Tumor Suppressor Proteins; 42HK56048U / Tyrosine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


17. Bleichner-Perez S, Le Jeune F, Dubois F, Steinling M: 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun; 2007 Dec;28(12):888-94
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors.
  • BACKGROUND: Malignant brain tumors carry a pejorative prognosis and necessitate aggressive therapy.
  • Chemotherapy can be used in cases of tumor recurrence.
  • With limited response rate and potential toxicity to chemotherapeutic treatment in patients with recurrent glioma, reliable response assessment is essential.
  • AIM: To define the place of 99mTc hexakis 2-methoxyisobutylisonitrile (99mTc-MIBI) Single Positron Emission Computed Tomography (SPECT) in monitoring chemotherapy response in recurrent primary brain tumors.
  • Imaging was performed 1h after the intravenous injection of 555 MBq of 99mTc-MIBI using a dedicated SPECT system.
  • CONCLUSION: This study confirms our previous results obtained on a short series of patients with recurrent glioma, concerning the usefulness of MIBI SPECT in prediction of chemotherapy response.
  • Moreover, in cases of tumor progression, we show that MIBI SPECT is an earlier indicator of escape from chemotherapy, an average 4 months before MRI changes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / radionuclide imaging. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090213.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


18. Le Jeune FP, Dubois F, Blond S, Steinling M: Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol; 2006 Apr;77(2):177-83
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies.
  • OBJECT: In the follow-up of treated gliomas, CT and MRI can often not differentiate radionecrosis from recurrent tumor.
  • METHOD: MIBI SPECT were performed in 81 patients treated for brain gliomas.
  • Eleven scans were false negative (5 patients): 1 patient with a deep peri-ventricular lesion, 2 patients with no contrast enhancement on MRI, 2 patients with a temporal tumor.
  • The sensitivity for tumor recurrence was 90%, specificity 91.5% and accuracy 90.5%.
  • We studied separately low and high grade glioma: sensitivity for tumor recurrence was respectively 91% and 89%, specificity 100% and 83% and accuracy 95% and 87%.
  • CONCLUSIONS: Our results confirm the usefullness of MIBI SPECT in the follow-up of treated gliomas for the differential diagnosis between radiation necrosis and tumor recurrence.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Glioma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adult. Aged. False Negative Reactions. False Positive Reactions. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Tomography, Emission-Computed, Single-Photon

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314957.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


19. McCall T, Rao G, Jensen R: Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma. J Neurooncol; 2006 Nov;80(2):167-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • We present the rare case of a desmoid tumor that occurred in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • A 30-year-old woman underwent a repeat suboccipital craniotomy for recurrent low-grade astrocytoma.
  • Histology demonstrated clear surgical margins and a tumor of low cellularity consistent with a desmoid tumor.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / pathology. Fibromatosis, Aggressive / pathology. Postoperative Complications / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Occipital Bone

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645711.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Chamberlain MC, Glantz MJ: Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery; 2008 Oct;63(4):720-6; author reply 726-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
  • OBJECTIVE: Hemangiopericytoma (HPC) is an uncommon primary brain tumor with an almost invariable tendency to recur and metastasize.
  • We undertook a retrospectively collected case series of recurrent intracranial HPCs treated with salvage chemotherapy with the primary objective of evaluating progression-free survival.
  • METHODS: Fifteen patients, ages 26 to 62 years, with recurrent HPC and who were previously treated with surgery and involved-field radiotherapy were studied.
  • CONCLUSION: Salvage chemotherapy demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent surgery- and radiotherapy-refractory intracranial HPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Hemangiopericytoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Cisplatin / adverse effects. Cisplatin / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Drug Administration Routes. Drug Administration Schedule. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Interferon-alpha / administration & dosage. Kaplan-Meier Estimate. Liposomes. Magnetic Resonance Spectroscopy. Male. Middle Aged. Positron-Emission Tomography. Rare Diseases. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981882.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Liposomes; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; CAV protocol; ICE protocol 1
  •  go-up   go-down


21. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol; 2007 Oct 20;25(30):4722-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
  • PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months.
  • After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab.
  • One patient developed a CNS hemorrhage, which occurred in his 10th cycle.
  • CONCLUSION: Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Apr;5(4):186-7 [18285760.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 10;26(32):5304-5; author reply 5305 [18854564.001]
  • [CommentIn] Nat Clin Pract Neurol. 2008 May;4(5):242-3 [18212790.001]
  • [CommentIn] J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013 [18281677.001]
  • (PMID = 17947719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 4 R37 CA11898; United States / NCI NIH HHS / CA / 5 P50 CA108786; United States / NINDS NIH HHS / NS / 5 P50 NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Kashimura H, Inoue T, Beppu T, Ogasawara K, Ogawa A: Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports. Clin Neurol Neurosurg; 2007 Jan;109(1):106-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports.
  • We describe two patients with tumor recurrence and one patient with radiation necrosis who were diagnosed using assessment of FA value.
  • The assessment of FA value in enhanced lesions after radiotherapy may be able to differentiate radiation necrosis from tumor recurrence.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Adult. Aged. Anisotropy. Female. Humans. Middle Aged. Necrosis. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793199.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol; 2010 Aug;12(8):855-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
  • The objective of this phase II single-arm study was to evaluate the efficacy and safety of pazopanib, a multi-targeted tyrosine kinase inhibitor, against vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor-alpha and -beta, and c-Kit, in recurrent glioblastoma.
  • Brain magnetic resonance imaging and clinical reassessment were made every 8 weeks.
  • Grade 3/4 toxicities included leukopenia (n = 1), lymphopenia (n = 2), thrombocytopenia (n = 1), ALT elevation (n = 3), AST elevation (n = 1), CNS hemorrhage (n = 1), fatigue (n = 1), and thrombotic/embolic events (n = 3); 8 patients required dose reduction.
  • Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients (6 at the 8-week point and 3 only within the first month of treatment) had decreased contrast enhancement, vasogenic edema, and mass effect but <50% reduction in tumor.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52 [2845420.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] PLoS One. 2009;4(4):e5123 [19352490.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • (PMID = 20200024.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00459381
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062421-12; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01RR03186; United States / NCI NIH HHS / CA / CA62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  • [Other-IDs] NLM/ PMC2940686
  •  go-up   go-down


24. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK: Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res; 2007 Dec 1;13(23):7133-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
  • PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites.
  • DESIGN: Patients with recurrent malignant glioma received a fixed dose of temozolomide (150 mg/m(2)) daily for 5 days from days 1 to 5 every 28 days, and an i.v. infusion of irinotecan on days 1 and 15 of each cycle.
  • Thirty-one patients were evaluable for both tumor response and toxicity and two patients were evaluable for toxicity only.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056194.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062426; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCI NIH HHS / CA / UM1 CA137443; United States / NCI NIH HHS / CA / U01CA62412; United States / NCI NIH HHS / CA / U01CA62426; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62399
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS761232; NLM/ PMC4802002
  •  go-up   go-down


25. Da Fonseca CO, Silva JT, Lins IR, Simão M, Arnobio A, Futuro D, Quirico-Santos T: Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs; 2009 Dec;27(6):557-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
  • BACKGROUND: The aim of this study was to establish a correlation of tumor topography and peritumoral brain edema with the therapeutic response to intranasal administration of perillyl alcohol (POH) in a cohort of patients with recurrent malignant gliomas.
  • METHODS: The retrospective study reviewed clinical and neuroradiological data from patients with recurrent malignant gliomas who received intranasal daily administration of POH 440 mg.
  • The following parameters were assessed: demographic characteristics, initial symptoms, overall survival, tumor topography and tumor size, presence of midline shift and extent of peritumoral edema.
  • Accordingly to tumor topography lobar localization was present in all (5/5) AO; eight (8/10) and 41 GBM patients whereas in the basal ganglia two AA and 11 GBM patients.
  • It was also observed a relation between the tumor size and area of peritumoral brain edema (PTBE).
  • Patients with good therapeutic response showed reduction of tumor size and PTBE area, but poor prognosis was associated with lack of response to treatment and persistence of high PTBE.
  • Patients with tumor in the basal ganglia survived significantly longer than those with lobar gliomas (log rank test, p = 0.0003).
  • (1) patients with recurrent gliomas with localization in the basal ganglia survive significantly longer than those with tumors at lobar localization;.
  • These findings support the theory that interaction between glioma cells at distinct brain microenvironment can influence the oncobiological behavior of glioma cells and ultimately to the prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Edema / pathology. Brain Neoplasms / drug therapy. Glioma / drug therapy. Glioma / pathology. Monoterpenes / therapeutic use. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Administration, Intranasal. Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139816.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Monoterpenes; 319R5C7293 / perilla alcohol
  •  go-up   go-down


26. Sheehan J, Kondziolka D, Flickinger J, Lunsford LD: Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg; 2005 Jan;102 Suppl:247-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors.
  • More than 50% of those with small cell lung cancer develop a brain metastasis.
  • In this study the authors examine the efficacy of gamma knife surgery for treating recurrent small cell lung carcinoma metastases to the brain following tumor growth in patients who have previously undergone radiation therapy, and they evaluate factors affecting survival.
  • METHODS: A retrospective review of 27 patients (47 recurrent small cell lung cancer brain metastases) undergoing radiosurgery was performed.
  • The overall median survival was 18 months after the diagnosis of brain metastases.
  • 1) tumor volume (p = 0.0042);.
  • 2) preoperative Karnofsky Performance Scale score (p = 0.0035); and 3) time between initial lung cancer diagnosis and development of brain metastasis (p = 0.0127).
  • Postradiosurgical imaging of the brain metastases revealed that 62% decreased, 19% remained stable, and 19% eventually increased in size.
  • One patient later underwent a craniotomy and tumor resection for a tumor refractory to radiosurgery and radiation therapy.
  • In three patients new brain metastases were demonstrating on follow-up imaging.
  • CONCLUSIONS: Stereotactic radiosurgery for recurrent small cell lung carcinoma metastases provided effective local tumor control in the majority of patients.
  • Early detection of brain metastases, aggressive treatment of systemic disease, and a therapeutic strategy including radiosurgery can extend survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Prospective Studies. Radiation Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662819.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed; 2005 Oct;18(6):371-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
  • Spectroscopic features of tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
  • Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments, more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g.
  • The present investigation demonstrated a correlation of the tCho-signal with tumor progression.
  • Significantly elevated concentrations of Ala (p = 0.037) and Glu (p = 0.003) and metabolite ratio tCho/tCr (p = 0.005) were even found in recurrent low-grade astrocytomas with unchanged histopathological grading (n = 11).
  • This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain tumor metabolism.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy / methods. Meningioma / metabolism. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Humans. Middle Aged. Protons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd
  • (PMID = 15959923.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


28. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther; 2009 Jan;17(1):199-207
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
  • We have previously demonstrated safety of G207, a doubly mutated (deletion of both gamma(1)34.5 loci, insertional inactivation of U(L)39) herpes simplex virus (HSV) for patients stereotactically inoculated in enhancing portions of recurrent malignant gliomas.
  • We have now determined safety of two inoculations of G207, before and after tumor resection.
  • Inclusion criteria were histologically proven recurrent malignant glioma, Karnofsky score >or=70, and ability to resect the tumor without ventricular system breach.
  • Patients received two doses of G207 totaling 1.15 x 10(9) plaque-forming units with 13% of this total injected via a catheter placed stereotactically in the tumor.
  • Two or five days later, tumor was resected en bloc with catheter in place.
  • The balance of G207 dose was injected into brain surrounding the resection cavity.
  • Six patients with recurrent glioblastoma multiforme were enrolled.
  • G207 appears safe for multiple dose delivery, including direct inoculation into the brain surrounding tumor resection cavity.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy. Simplexvirus / physiology
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Aged. Antibodies, Viral / blood. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome. Virus Replication

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):958-66 [15509513.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):654-8 [3021931.001]
  • [Cites] Science. 1991 May 10;252(5007):854-6 [1851332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):597-603 [8386343.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4752-6 [7585498.001]
  • [Cites] Gene Ther. 1994;1 Suppl 1:S78 [8542424.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1354-61 [9396605.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4457-64 [9574551.001]
  • [Cites] Gene Ther. 1998 Feb;5(2):160-5 [9578834.001]
  • [Cites] Hum Gene Ther. 1999 Feb 10;10(3):385-93 [10048391.001]
  • [Cites] Microbiol Immunol. 1999;43(2):177-80 [10229273.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1517-22 [10389941.001]
  • [Cites] J Virol. 1999 Aug;73(8):6319-26 [10400723.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] J Neurooncol. 1999 May;43(1):71-8 [10448874.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):38-50 [16391370.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E4 [16709035.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):739-44 [16891823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12873-8 [16908838.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2741-55 [10584921.001]
  • [Cites] Rev Med Virol. 2000 Jan-Feb;10(1):17-30 [10654002.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13 [10681459.001]
  • [Cites] J Virol. 2000 Apr;74(8):3832-41 [10729157.001]
  • [Cites] J Neurosurg. 2000 May;92(5):804-11 [10794295.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • [Cites] Med Microbiol Immunol. 2002 Mar;190(4):153-60 [12005327.001]
  • [Cites] BMC Infect Dis. 2004 Mar 17;4:10 [15113449.001]
  • [Cites] Gene Ther. 2004 Nov;11(22):1648-58 [15334111.001]
  • [CommentIn] Mol Ther. 2009 Jan;17(1):8-9 [19116635.001]
  • (PMID = 18957964.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA071933; United States / NCI NIH HHS / CA / P50 CA097247; United States / NCI NIH HHS / CA / P01 CA71933
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; X4HES1O11F / Acyclovir
  • [Other-IDs] NLM/ PMC2834981
  •  go-up   go-down


29. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K: Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med; 2008 May;49(5):694-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.
  • We evaluated the diagnostic accuracy of PET with l-methyl-(11)C-methionine ((11)C-MET) for the differentiation of recurrent brain tumors from radiation necrosis.
  • METHODS: Seventy-seven patients who had been previously treated with radiotherapy after primary treatment for metastatic brain tumor (n=51) or glioma (n=26) were studied to clarify the diagnostic performance of (11)C-MET PET in differentiating between recurrent brain tumors and radiation necrosis.
  • A total of 88 PET scans with (11)C-MET were obtained; sometimes more than one scan was obtained when there was an indication of recurrent brain tumor or radiation necrosis.
  • A definitive diagnosis was made on the basis of pathologic examination for recurrent brain tumors and on the basis of pathologic examination or clinical course for radiation necrosis.
  • Receiver-operating-characteristic (ROC) curve analysis was used to determine the optimal index of (11)C-MET PET and cutoff values for the differential diagnosis of tumor recurrence and radiation necrosis.
  • RESULTS: The values of each index of (11)C-MET PET tended to be higher for tumor recurrence than for radiation necrosis.
  • There were significant differences between tumor recurrence and radiation necrosis in all of the indices except for the L/N(max) for glioma.
  • ROC analysis indicated that the L/N(mean) was the most informative index for differentiating between tumor recurrence and radiation necrosis.
  • An L/N(mean) of greater than 1.41 provided the best sensitivity and specificity for metastatic brain tumor (79% and 75%, respectively), and an L/N(mean) of greater than 1.58 provided the best sensitivity and specificity for glioma (75% and 75%, respectively).
  • CONCLUSION: (11)C-MET PET can provide quantitative values to aid in the differentiation of tumor recurrence from radiation necrosis, although these values do not appear to be absolute indicators.
  • Quantitative analysis of (11)C-MET PET data may be helpful in managing irradiated brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Methionine. Necrosis / diagnosis. Necrosis / etiology. Positron-Emission Tomography / methods. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carbon Radioisotopes. Diagnosis, Differential. Female. Glioma / diagnosis. Glioma / secondary. Humans. Male. Middle Aged. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2008 Oct;49(10):1733-4; author reply 1734 [18794274.001]
  • (PMID = 18413375.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


30. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, North American Brain Tumor Consortium: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol; 2006 Apr;8(2):189-93
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
  • Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible.
  • No more than one prior chemotherapy was allowed, either as adjuvant therapy or for recurrent disease.
  • Patients with stable or responding disease could be treated until tumor progression or a total of 12 months of therapy.
  • The primary end point of the study was to determine whether CPT-11 could significantly delay tumor progression, using the rate of six-month progression-free survival (PFS-6).

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 1999 Oct;1(4):282-8 [11550320.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):603-14 [12649109.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):187-91 [8996518.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):440-4 [9054958.001]
  • [Cites] Drug Metab Dispos. 1998 Aug;26(8):769-74 [9698291.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • (PMID = 16533878.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062399; United States / NCI NIH HHS / CA / CA 62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC1871932
  •  go-up   go-down


31. Weller M: [Chemotherapy for brain tumors in adult patients]. Nervenarzt; 2008 Feb;79(2):231-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for brain tumors in adult patients].
  • Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy.
  • The role of chemotherapy in the treatment of gliomas is no longer limited to recurrent disease.
  • Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy.
  • The chemotherapy of brain metastases follows the recommendations for the respective primary tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Genetic Markers / genetics. Humans. Prognosis. Promoter Regions, Genetic / genetics. Topotecan / adverse effects. Topotecan / therapeutic use. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253773.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


32. Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E: Recurrent central neurocytomas. Cancer; 2005 Jul 1;104(1):135-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent central neurocytomas.
  • BACKGROUND: Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease.
  • RESULTS: Between 1985-2003. surgical resection was performed in 14 patients with CNs ages 16-43 years (7 were female and 7 were male).
  • The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor.
  • CONCLUSIONS: CNs appear to have a higher tendency to recur during long-term follow-up than previously reported, even after complete resection.
  • [MeSH-major] Brain Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neurocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD: Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol; 2008 Jun;10(3):320-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
  • The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brain tumors using the intracerebral infusion technique of convection-enhanced delivery (CED).
  • Twenty patients were enrolled and stratified for dose escalation by the presence of residual tumor from 25 to 100 ng/ml in a 40-ml infusion volume.
  • In the last eight patients, coinfusion of (123)I-albumin was performed to monitor distribution within the brain.
  • CED has significant potential for enhancing delivery of therapeutic macromolecules throughout the human brain.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 May;9(5):589-95 [12669033.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:93-103 [14531567.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):893-8 [14609170.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):27-35 [14649883.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5514-20 [14654531.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):197-201 [15015787.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):472-9 [15035283.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2572-9 [15059914.001]
  • [Cites] J Neurooncol. 2004 May;68(1):1-9 [15174514.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6858-62 [15466173.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s [2404582.001]
  • [Cites] Front Radiat Ther Oncol. 1990;24:32-46; discussion 64-8 [2187763.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Ann Neurol. 1990 Dec;28(6):818-22 [2178330.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):253-66 [2292138.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(1):61-4 [2021959.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1173-7 [1683495.001]
  • [Cites] APMIS. 1992 Aug;100(8):713-9 [1520484.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R292-305 [8304553.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):1008-15 [8313355.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):520-6 [8113865.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5631-7 [8971168.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):586-94 [9322847.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):C1-6 [9395287.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Curr Top Microbiol Immunol. 1998;234:97-114 [9670615.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):321-31 [9950504.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 2):R1218-29 [10516265.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1004-11 [15597761.001]
  • [Cites] Ann Neurol. 2005 Feb;57(2):298-302 [15668979.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):90-6 [15701286.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):326-34 [10690507.001]
  • [Cites] Leukemia. 2000 Apr;14(4):576-85 [10764142.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1622-36 [10764422.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2157-65 [10873064.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4148-53 [11051269.001]
  • [Cites] Cell Transplant. 2000 Sep-Oct;9(5):585-94 [11144956.001]
  • [Cites] Exp Neurol. 2001 Mar;168(1):155-61 [11170730.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):45-59 [11302254.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1243-52; discussion 1252-3 [15918940.001]
  • [Cites] Nat Med. 2005 Jul;11(7):703-4 [16015352.001]
  • [Cites] Exp Neurol. 2005 Aug;194(2):476-83 [16022872.001]
  • [Cites] J Neurosurg. 2005 Nov;103(5):923-9 [16304999.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3145-51 [16707614.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):343-53 [17435179.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3039-51 [3555767.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):125-37 [12952293.001]
  • (PMID = 18403491.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCRR NIH HHS / RR / K23 RR016065; United States / NCRR NIH HHS / RR / K23 RR16065; United States / NCRR NIH HHS / RR / S10 RR15697; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA11898; United States / NCI NIH HHS / CA / R01 CA097611; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NCI NIH HHS / CA / P50-CA097257; United States / NINDS NIH HHS / NS / 2P50-NS20023; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Exotoxins; 0 / Immunotoxins; 0 / Transforming Growth Factor alpha; 0 / transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38); EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2563054
  •  go-up   go-down


34. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • METHODS: Forty patients (28 men, 12 women) ages 26-57 years (median, 43 yrs) with neuroradiographically recurrent AA were treated.
  • Time to tumor progression ranged from 2-19 months (median, 4 mos; 95% CI, 2-6 mos).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Anaplasia. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


35. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol; 2005 Feb;71(3):319-23
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
  • PURPOSE: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG).
  • PATIENTS AND METHODS: Sixty-three patients were treated with fractionated stereotactic re-irradiation in the case of recurrent gliomas.
  • At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
  • CONCLUSION: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent glioma represents an effective treatment option with good results and few complications.
  • However, further investigation is warranted to consolidate these results and to combine radiation with chemotherapy in the case of recurrent LGG.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retreatment. Retrospective Studies. Stereotaxic Techniques / instrumentation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735924.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Jain R, Scarpace L, Ellika S, Schultz LR, Rock JP, Rosenblum ML, Patel SC, Lee TY, Mikkelsen T: First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery; 2007 Oct;61(4):778-86; discussion 786-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis.
  • OBJECTIVE: To differentiate recurrent tumors from radiation effects and necrosis in patients with irradiated brain tumors using perfusion computed tomographic (PCT) imaging.
  • METHODS: Twenty-two patients with previously treated brain tumors who showed recurrent or progressive enhancing lesions on follow-up magnetic resonance imaging scans and had a histopathological diagnosis underwent first-pass PCT imaging (26 PCT imaging examinations).
  • RESULTS: Fourteen patients were diagnosed with recurrent tumor, and eight patients had radiation necrosis.
  • There was a statistically significant difference between the two groups, with the recurrent tumor group showing higher mean nCBV (2.65 versus 1.10) and nCBF (2.73 versus 1.08) and shorter nMTT (0.71 versus 1.58) compared with the radiation necrosis group.
  • For nCBV, a cutoff point of 1.65 was found to have a sensitivity of 83.3% and a specificity of 100% to diagnose recurrent tumor and radiation necrosis.
  • Similar sensitivity and specificity were 94.4 and 87.5%, respectively, for nCBF with a cutoff point of 1.28 and 94.4 and 75%, respectively, for nMTT with a cutoff point of 1.44 to diagnose recurrent tumor and radiation necrosis.
  • CONCLUSION: PCT may aid in differentiating recurrent tumors from radiation necrosis on the basis of various perfusion parameters.
  • Recurrent tumors show higher nCBV and nCBF and lower nMTT compared with radiation necrosis.
  • [MeSH-major] Brain Neoplasms / radiography. Perfusion / methods. Radiation Injuries / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Cranial Irradiation / adverse effects. Female. Humans. Male. Middle Aged. Necrosis. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986939.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res; 2008 Apr 15;14(8):2378-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary biomarkers predict brain tumor presence and response to therapy.
  • PURPOSE: A major difficulty in treating brain tumors is the lack of effective methods of identifying novel or recurrent disease.
  • In this study, we have evaluated the efficacy of urinary matrix metalloproteinases (MMP) as diagnostic biomarkers for brain tumors.
  • EXPERIMENTAL DESIGN: Urine, cerebrospinal fluid, and tissue specimens were collected from patients with brain tumors.
  • RESULTS: Evaluation of a specific panel of urinary biomarkers by ELISA showed significant elevations of MMP-2, MMP-9, MMP-9/NGAL, and VEGF (all P < 0.001) in samples from brain tumor patients compared with controls.
  • Immunohistochemistry identified these same proteins in the source tumor tissue.
  • A subset of patients with longitudinal follow-up revealed subsequent clearing of biomarkers after tumor resection.
  • CONCLUSION: We report, for the first time, the identification of a panel of urinary biomarkers that predicts the presence of brain tumors.
  • These data support the hypothesis that urinary MMPs and associated proteins are useful predictors of the presence of brain tumors and may provide a basis for a novel, noninvasive method to identify new brain tumors and monitor known tumors after treatment.
  • [MeSH-major] Acute-Phase Proteins / urine. Biomarkers, Tumor / urine. Brain Neoplasms / diagnosis. Lipocalins / urine. Matrix Metalloproteinase 2 / urine. Matrix Metalloproteinase 9 / urine. Proto-Oncogene Proteins / urine. Vascular Endothelial Growth Factor A / urine
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Longitudinal Studies. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413828.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK065298; United States / NCI NIH HHS / CA / K12CA90354; United States / NCI NIH HHS / CA / P01CA45548
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


38. Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE: A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol; 2008 Mar;87(1):85-90
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
  • PURPOSE: To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors.
  • METHODS: Patients > or =18 years of age and with Karnofsky performance scale (KPS) > or = 60, adequate organ function and progressive or recurrent brain metastases were eligible.
  • The primary tumor sites were lung (n = 20), breast (n = 11), colorectal (n = 2), kidney (n = 2), bladder (n = 1), endometrium (n = 1), head and neck (n = 1).
  • Prior therapies included chemotherapy (97%), whole-brain radiation therapy (79%), brain metastasis resection (53%) and stereotatic radiosurgery (47%).
  • CONCLUSIONS: In this heavily pretreated population of patients with brain metastases, adding vinorelbine and increasing the intensity of temozolomide do not improve response rates compared to previous studies with single-agent temozolomide at standard doses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Survival Analysis. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987262.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


39. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer; 2010;10:30
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
  • BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months.
  • Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare.
  • METHODS: We performed a retrospective analysis of 35 patients with recurrent or progressive glioblastoma treated with 80 mg/m2 BCNU on days 1 on 3 intravenously at our department for efficacy, toxicity and prognostic factors.
  • The influence of age, Karnofsky performance status (KPS), tumor burden, pretreatment with temozolomide (TMZ), type of surgery for initial diagnosis and number of previous relapses on outcome was analyzed in a proportional hazards regression model.
  • No influence of age, KPS, tumor burden, pre-treatment with TMZ and number of previous relapses on outcome could be demonstrated, while gross total resection prior to recurrence showed a borderline statistically significant negative impact on PFS and OS.
  • CONCLUSION: In summary, BCNU treatment appears to be a valuable therapeutic option for recurrent glioblastomas, where no other validated radio- and/or chemotherapy are available.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / pharmacology. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1998 Feb;168(2):114-20 [9499745.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9 [15990019.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):210-7 [16175848.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2168-73 [16220556.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):29-37 [16378904.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E5 [16709036.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):57-62 [19212704.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):161-71 [11508816.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Mutat Res. 1985 Jan-Mar;145(1-2):1-16 [3883145.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):654-8 [3021931.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):607-14 [2827051.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):573-7 [2926498.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):583-91 [1429079.001]
  • [Cites] Clin Neuropathol. 1999 Jan-Feb;18(1):1-8 [9988132.001]
  • (PMID = 20122270.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2837009
  •  go-up   go-down


40. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol; 2007 Apr;9(2):145-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
  • This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs).
  • Twenty-four evaluable patients received therapy before the amendment, and three of six with a brainstem tumor experienced dose-limiting toxicity (DLT): one had asymptomatic ITH, one had grade 4 neutropenia and, one had renal insufficiency.
  • None of 18 patients with recurrent glioma experienced DLT.
  • After protocol amendment, 3 of 16 patients with brainstem glioma and 2 of 11 patients with recurrent glioma who were not receiving EIACDs experienced ITH DLTs, with three patients being symptomatic.
  • The MTD for recurrent high-grade gliomas without EIACDs was 465 mg/m(2), but the MTD was not established with EIACDs, with no DLTs at 800 mg/m(2).
  • In summary, recommended phase II imatinib doses were determined for children with newly diagnosed brainstem glioma and recurrent high-grade glioma who were not receiving EIACDs.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):398-406 [10652433.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):65-9 [15712639.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2929-34 [11306470.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):325-40 [11888061.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3431-7 [12177103.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7377-83 [14612536.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23 [14658008.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):896-902 [3338054.001]
  • [Cites] Cancer Lett. 1988 Jan;38(3):283-96 [3258178.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):1-12 [2156959.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Neuroradiology. 1990;32(4):265-71 [2234384.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):284-93 [1649272.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Childs Nerv Syst. 1991 Dec;7(8):432-6 [1665101.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1414-21 [8339232.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):309-14; discussion 314-5 [8177392.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6106-14 [7954456.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Stat Med. 1995 Jun 15;14(11):1149-61 [7667557.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):207-22 [8832463.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] Pediatr Neurosurg. 1998 Nov;29(5):228-44 [9917540.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1464-72 [10197615.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • (PMID = 17293590.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01 RR00188-37; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC1871662
  •  go-up   go-down


41. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2008 May 1;112(9):2038-45
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).
  • METHODS: Forty patients (27 men and 13 women) ages 17 to 58 years (median age, 38 years) with radiographically recurrent AA were treated.
  • The median time to tumor progression was 4.1 month.
  • CONCLUSIONS: CPT-11 demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent AA, all of whom had failed on prior temozolomide chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE: Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol; 2006 Jul;78(3):277-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
  • Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM).
  • Patients with recurrent or progressive BM were eligible.
  • The primary tumor was lung cancer in 13 patients (NSCLC in 10, SCLC in 3), breast in 6, renal in 1 and endometrial in 1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphopenia / chemically induced. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614943.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


43. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand; 2008 Mar;117(3):191-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.
  • Materials and Methods - Boron uptake in recurrent GBM was measured for four patients.
  • BNCT was well tolerated and quality of life remained stable until tumor progression for all 12 patients.
  • No correlation was found between survival times and minimum tumor dose and number of radiation fields.
  • Conclusions - Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Body Weight. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297764.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


44. VanderSpek L, Fisher B, Bauman G, Macdonald D: 3D conformal radiotherapy and cisplatin for recurrent malignant glioma. Can J Neurol Sci; 2008 Mar;35(1):57-64
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3D conformal radiotherapy and cisplatin for recurrent malignant glioma.
  • PURPOSE: To determine the maximum tolerated dose of 3D conformal radiotherapy in combination with Cisplatin for patients with recurrent malignant gliomas.
  • METHODS: From 1999-2003, nine patients with recurrent malignant glioma received fractionated radiotherapy and Cisplatin (20 mg/m2/d IV on days 1-5) in a Phase I radiation dose escalation trial.
  • The median re-irradiated tumor volume was 18.9 (0.1-78.5) cm3 and the median follow-up was 8.8 (3.2-31.2) months.
  • A second patient (35 Gy/ 7 fractions) experienced acute grade 2 toxicity and histology showed tumor and radiation effect.
  • This regimen demonstrated only modest efficacy in the treatment of recurrent malignant glioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cisplatin / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Endpoint Determination. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380278.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


45. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Twenty-five patients (15 men; 10 women) ages 26-63 (median 50), with radiographically recurrent AA were treated.
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator refractory AA.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


46. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology; 2008 Mar 4;70(10):779-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
  • BACKGROUND: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas.
  • At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor.
  • METHODS: We retrospectively reviewed 55 consecutive patients with recurrent malignant gliomas who received bevacizumab and chemotherapy to determine efficacy, toxicity, and patterns of recurrence.
  • Recurrence pattern analysis identified a significant increase in the volume of infiltrative tumor relative to enhancing tumor in bevacizumab responders.
  • CONCLUSIONS: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas.
  • Bevacizumab may alter the recurrence pattern of malignant gliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / toxicity. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Brain / drug effects. Brain / pathology. Brain / physiopathology. Clinical Trials as Topic / statistics & numerical data. Disease-Free Survival. Drug Resistance, Neoplasm / physiology. Drug Synergism. Female. Humans. Magnetic Resonance Imaging. Male. Meta-Analysis as Topic. Middle Aged. Retrospective Studies. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2009 Feb 24;72(8):773; author reply 773-4 [19248218.001]
  • [CommentIn] Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4 [19237713.001]
  • (PMID = 18316689.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


47. Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Seog Heo D, Bang YJ: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer; 2010;10:448
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.
  • BACKGROUND: Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent neuroendocrine tumor (NET) have been few.
  • METHODS: We enrolled patients with metastatic/recurrent NET diagnosed between January 1996 and July 2007 and retrospectively analyzed.
  • CONCLUSIONS: OS of metastatic/recurrent NET was different according to tumor grade.
  • [MeSH-major] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


48. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol; 2009 Feb 10;27(5):740-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
  • PURPOSE: To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma.
  • PATIENTS AND METHODS: Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg every 2 weeks.
  • After tumor progression, patients were immediately treated with bevacizumab in combination with irinotecan 340 mg/m(2) or 125 mg/m(2) every 2 weeks, depending on use of enzyme-inducing antiepileptic drugs.
  • CONCLUSION: We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurooncol. 2001 Nov;55(2):91-100 [11817706.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1345-51 [1705174.001]
  • [Cites] J Neurosurg. 1992 May;76(5):792-8 [1564542.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):266 [15889502.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1426-30 [15919202.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):644-7 [16988588.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • (PMID = 19114704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2645088
  •  go-up   go-down


49. Hattingen E, Franz K, Pilatus U, Weidauer S, Lanfermann H: Postictal spectroscopy and imaging findings mimicking brain tumor recurrence. J Magn Reson Imaging; 2006 Jul;24(1):226-30
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postictal spectroscopy and imaging findings mimicking brain tumor recurrence.
  • (1)H magnetic resonance spectroscopic imaging (MRSI) was performed on a patient with an admission diagnosis of recurrent astrocytoma.
  • MRSI revealed a marked increase of trimethylamines (TMA), elevated creatine/creatinephosphate (tCr), and reduced N-acetyl-aspartate (tNAA) in the same brain region.
  • The spectroscopic data were consistent with tumor recurrence.
  • However, the pattern of contrast enhancement on magnetic resonance imaging (MRI), evidence of an epileptic focus on electroencephalography (EEG), and spontaneous regression of the symptoms argued against tumor recurrence.
  • This is the first report of seizure-induced MRS abnormalities mimicking tumor recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Seizures / pathology. Spectrophotometry / methods
  • [MeSH-minor] Adult. Aphasia / diagnosis. Aphasia / pathology. Astrocytoma / diagnosis. Astrocytoma / pathology. Contrast Media / pharmacology. Diagnosis, Differential. Electroencephalography / methods. Headache / pathology. Humans. Magnetic Resonance Imaging / methods. Paresis / diagnosis. Paresis / pathology. Recurrence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16739121.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


50. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol; 2006 Jul;78(3):271-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent meningioma.
  • BACKGROUND: A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma.
  • METHODS: Sixteen patients (5 men; 11 women) ages 48-70 years (median 62.5), with recurrent meningioma were treated.
  • Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months).
  • Using CPT-11 in this moderately toxic dose schedule failed to demonstrate efficacy in this cohort of adult patients with recurrent surgery and radiotherapy-refractory meningioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628476.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


51. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol; 2007 Feb;81(3):271-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
  • BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).
  • OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM.
  • PATIENTS AND METHODS: Eligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. North America. Survival Analysis. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031561.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


52. Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M: Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol; 2005 Sep 20;23(27):6647-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
  • PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs).
  • PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme.
  • [MeSH-major] Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinolones / administration & dosage. Salvage Therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Anticonvulsants / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170172.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455-08; United States / NCI NIH HHS / CA / CA76292; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / U01CA62422
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Quinolones; 192185-72-1 / tipifarnib
  •  go-up   go-down


53. Maiuri F, Del Basso De Caro M, Siciliano A, Peca C, Vergara P, Mariniello G, Pettinato G: Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival. Clin Neuropathol; 2010 Mar-Apr;29(2):109-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
  • OBJECTIVE: The aim of this study is to evaluate the correlation between the expression of some growth factors (GFs) and the tumor grade, recurrence and survival of brain glial and ependymal tumors.
  • MATERIAL AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tenascine, transforming growth factor (TGFbeta), isomeres, platelet-derived growth factor (PDGF) and p53 was studied in 40 primary brain tumors, both low-grade and high-grade, including astrocytomas, oligodendrogliomas, glioblastomas and ependymomas.
  • The same GFs were also studied in 46 specimens of recurrent tumors from the same patients.
  • The positivity and intensity of the immunohistochemical expression were correlated with the tumor grade, the interval and type of recurrence, and the survival.
  • RESULTS: The expression of all GFs, excepting TGFbeta1, TGFbetaRI and tenascine, was found to be correlated with the tumor grade in all tumors of both astroglial and oligodendroglial origin, whereas ependymomas showed significant differences only for EGFR.
  • CONCLUSION: The immunohistochemical study of expression of VEGF, EGFR, TGFbeta2, TGFbeta3, PDGF and p53 in all low-grade (Grade II) brain gliomas at the first operation may help to differentiate cases with slower evolution and longer survival from those with higher potential of anaplastic transformation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175962.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


54. Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC: Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol; 2009 Feb;192(2):W45-52
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.
  • OBJECTIVE: Differentiation between recurrent neoplasm and postradiation change in patients previously treated for primary brain tumors is often difficult based on imaging features alone.
  • The purpose of this study was to develop a method using alterations in the ratios of standard brain metabolites-choline (Cho), creatine (Cr), and N-acetylaspartate (NAA)-to predict the probability of tumor recurrence in patients previously treated for brain tumors with new contrast-enhancing lesions.
  • MATERIALS AND METHODS: Thirty-three patients who had undergone treatment for primary brain tumors in whom routine MRI showed new contrast-enhancing lesions were retrospectively studied.
  • RESULTS: Elevations of the metabolic ratios Cho/Cr (p < 0.001) and Cho/NAA (p < 0.001) and a decrease in the ratio NAA/Cr (p = 0.018) were found in patients with recurrent tumor (n = 20) versus those with postradiation change (n = 13).
  • CONCLUSION: An elevated Cho/NAA ratio correlated with evidence of tumor recurrence and allowed creation of a prediction rule to aid in lesion classification.
  • [MeSH-major] Brain Neoplasms / metabolism. Decision Support Systems, Clinical. Magnetic Resonance Spectroscopy / methods. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Child. Child, Preschool. Choline / metabolism. Contrast Media. Creatine / metabolism. Female. Gadolinium. Humans. Logistic Models. Male. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2009 Dec;193(6):W569-70 [19933634.001]
  • (PMID = 19155380.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; AU0V1LM3JT / Gadolinium; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


55. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, An HX: Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep; 2008 Jan;19(1):151-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
  • Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor characterized by excessive angiogenesis.
  • The EphA2 receptor tyrosine kinase plays a pivotal role in tumor angiogenesis and an increased expression in glioma patients has recently been reported.
  • In this study, we investigated the expression of EphA2 in human normal brain, primary and recurrent GBM and correlated it with clinical pathological parameters and patient's outcome.
  • A different intensity of the membranous and cytoplastic expression of EphA2 was observed in the 40 primary and recurrent samples of GBM analyzed but not in the normal brain.
  • A high level expression of EphA2 was demonstrated in 24 (60%) of the primary and recurrent GBM analyzed.
  • The data presented in this study define the expression pattern of EphA2 in both primary and recurrent glioblastoma and suggest an important role of EphA2 in the pathogenesis of GBM.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Receptor, EphA2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097589.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


56. Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y: Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery; 2006 Nov;59(5):949-55; discussion 955-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy.
  • The system delivers small volumetric sonications from an ultrasound phased array transmitter that focuses energy selectively to destroy the target with verification by magnetic resonance imaging-generated thermal maps.
  • A Phase I clinical study was initiated to treat patients with recurrent glioma with MRIgFUS.
  • METHODS: To date, three patients with histologically verified recurrent glioblastoma multiforme have been treated with MRIgFUS.
  • Sonications were applied to induce thermocoagulation of the enhancing tumor mass.
  • In one patient, heating of brain tissue in the sonication path resulted in a secondary focus outside the target causing neurological deficit.
  • CONCLUSION: In this first clinical report, MRIgFUS was demonstrated to be a potentially effective means of destroying tumor tissue by thermocoagulation, although with an associated morbidity and the inherent invasive nature of the procedure requiring creation of a bone window.
  • [MeSH-major] Brain Neoplasms / therapy. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Ultrasonic Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143231.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg; 2008 May;108(5):963-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
  • OBJECT: The object of this study was to investigate the safety and clinical responses of immunotherapy targeting the WT1 (Wilms tumor 1) gene product in patients with recurrent glioblastoma multiforme (GBM).
  • METHODS: Twenty-one patients with WT1/HLA-A*2402-positive recurrent GBM were included in a Phase II clinical study of WT1 vaccine therapy.
  • Tumor size, which was obtained by measuring the contrast-enhanced area on magnetic resonance images, was determined every 4 weeks.
  • Patients who achieved an effective response continued to be vaccinated until tumor progression occurred.
  • CONCLUSIONS: Although a small uncontrolled nonrandomized trial, this study showed that WT1 vaccine therapy for patients with WT1/HLA-A*2402-positive recurrent GBM was safe and produced a clinical response.
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Injections, Intradermal. Male. Middle Aged. Treatment Outcome. Vaccination

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447714.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Nuclear Proteins; 0 / WTAP protein, human
  •  go-up   go-down


58. Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K, Kochi M, Morishita S, Yamashita Y: Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol; 2005 Jun-Jul;26(6):1455-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence.
  • BACKGROUND AND PURPOSE: Differentiation between tumor recurrence and treatment-related brain injury is often difficult with conventional MRI.
  • We hypothesized that the diffusion-weighted imaging (DWI) could help differentiate these 2 conditions, because water diffusion may be greater for necrotic tissues in the treatment-related brain injury than for tumor tissues in recurrence.
  • Our aim was to analyze whether DWI findings of recurrent tumor are distinct from those of radiation necrosis.
  • RESULTS: There were a total of 20 lesions; 12 lesions were due to radiation necrosis and 8 lesions to tumor recurrence.
  • Significant difference was found in the maximal ADC values between radiation necrosis and tumor recurrence.
  • DWI was useful in differentiating recurrent neoplasm from radiation necrosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Radiation-Induced / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1305 [15956484.001]
  • (PMID = 15956515.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Estrada G, González-Maya L, Celis-López MA, Gavito J, Lárraga-Gutiérrez JM, Salgado P, Altamirano J: Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico. Rev Esp Med Nucl; 2008 Sep-Oct;27(5):329-39
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico.
  • PET uptake was determined by visual inspection and was quantified by use of standard uptake values, the ratio of tumor uptake to normal tissue and were z scored using automated voxel-based comparison.
  • CONCLUSIONS: (18)FDG SUVs, glucose uptake ratios and 3D stereotactic surface projections in brain tumors were not a reliable measure for evaluating recurrent tumors.
  • PET/MRI fusion was more sensitive and accurate than PMRI for imaging recurrent primary brain tumors.
  • The region of interest can be visually analyzed on the PET/MRI fusion images and described as recurrent tumor when any activity (lower, equal or greater than the contralateral cortex) is presented in the zone of hyperintensity seen on the post-gadolinium T1-weighted MRI.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fluorodeoxyglucose F18. Imaging, Three-Dimensional. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Mexico. Middle Aged. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18817662.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Kalapurakal JA, Goldman S, Stellpflug W, Curran J, Sathiaseelan V, Marymont MH, Tomita T: Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):800-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy).
  • PURPOSE: To describe the preliminary results after intraoperative radiotherapy (IORT) with the photon radiosurgery system in children with recurrent brain tumors treated at the first dose level (10 Gy) of a Phase I protocol.
  • METHODS AND MATERIALS: A Phase I IORT dose escalation protocol was initiated at Children's Memorial Hospital to determine the maximal tolerated IORT dose in children with recurrent brain tumors.
  • Eight patients (57%) had tumor control within the surgical bed after IORT.
  • CONCLUSION: Our findings have demonstrated the safety and feasibility of IORT to a dose of 10 Gy to 2 mm in children with previously irradiated brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Photons / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Brain / radiation effects. Child. Ependymoma / radiotherapy. Ependymoma / surgery. Feasibility Studies. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Necrosis / etiology. Radiation Injuries / etiology. Radiosurgery / instrumentation. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580791.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
  • Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients.
  • CONCLUSION: BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


62. Clavreul A, Piard N, Tanguy JY, Gamelin E, Rousselet MC, Leynia P, Menei P: Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci; 2010 Jul;17(7):842-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.
  • We report on the safety and feasibility of autologous tumor cell vaccination combined with infusion of granulocyte-macrophage colony-stimulating factor by a programmable pump in the treatment of recurrent malignant gliomas.
  • [MeSH-major] Brain Neoplasms / drug therapy. Cancer Vaccines / therapeutic use. Glioma / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Infusion Pumps, Implantable. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Immunotherapy, Adoptive / instrumentation. Immunotherapy, Adoptive / methods. Male. Middle Aged. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20466548.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


63. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, Mikkelsen T: Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol; 2010 Sep;99(2):237-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
  • After withdrawal of bevacizumab in patients with recurrent high-grade glioma, we have observed a rapid tumour re-growth or "rebound" radiographic phenomenon with accelerated clinical decline.
  • We retrospectively reviewed 11 patients treated at the Henry Ford Hermelin Brain Tumor Center with recurrent high-grade glioma who demonstrated a rebound progression pattern after the discontinuation of bevacizumab.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Withholding Treatment

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20151176.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


64. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA, New Approaches to Brain Tumor Therapy (NABTT) Consortium: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol; 2010 Nov;100(2):261-8
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
  • A phase I/II and pharmacokinetic trial of ixabepilone was conducted in patients with recurrent high-grade gliomas.
  • Adult patients received ixabepilone as a 1-h infusion daily for 5 days every 3 weeks.
  • Ixabepilone had no activity in patients with recurrent high-grade gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6233-9 [16144926.001]
  • [Cites] J Neurooncol. 1999 May;43(1):71-8 [10448874.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):327-34 [17347871.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 5:v28-34 [17656559.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2701-9 [18451235.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • [Cites] Drug Metab Dispos. 2002 Jul;30(7):795-804 [12065438.001]
  • [Cites] Drug Metab Dispos. 2003 May;31(5):533-9 [12695340.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Drug Metab Dispos. 2004 Mar;32(3):348-58 [14977870.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):249-55 [1823867.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] J Antibiot (Tokyo). 1996 Jun;49(6):560-3 [8698639.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2316-21 [8708723.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3344-6 [9269992.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6647-56 [16170172.001]
  • [Cites] Clin Pharmacokinet. 2005;44(3):279-304 [15762770.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):429-36 [9554585.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] J Clin Pharm Ther. 1999 Apr;24(2):87-92 [10380060.001]
  • [ErratumIn] J Neurooncol. 2010 Nov;100(2):269. Mikkelson, Tom [corrected to Mikkelsen, Tom]
  • (PMID = 20449631.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / UL1 RR025005; United States / NCI NIH HHS / CA / CA62475; United States / NCRR NIH HHS / RR / UL1 RR 025005
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ NIHMS521307; NLM/ PMC3811044
  •  go-up   go-down


65. Moviglia GA, Carrizo AG, Varela G, Gaeta CA, Paes de Lima A, Farina P, Molina H: Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):3-13
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme.
  • BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance.
  • Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells.
  • RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation.
  • Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation.
  • A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone.
  • CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction.
  • [MeSH-major] B-Lymphocytes / transplantation. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Glioblastoma / therapy. Hybridomas / transplantation. Neoplastic Stem Cells / transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / transplantation. Lymphocyte Culture Test, Mixed. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063522.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


66. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
  • This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Compassionate Use Trials. Delayed-Action Preparations. Drug Resistance, Neoplasm. Female. Humans. Infant. Injections, Spinal. Liposomes / administration & dosage. Male. Retrospective Studies. Salvage Therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


67. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D: Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer; 2005 Nov 15;104(10):2168-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
  • BACKGROUND: This article describes the results of a study of stereotactic radiosurgery (SRS) in the treatment of patients with recurrent malignant glioma.
  • METHODS: Thirty-two patients with recurrent glioblastoma multiforme (GBM) were treated for 36 lesions with SRS from 1993 to 2001.
  • The median age at primary diagnosis of the tumor was 56 years (range, 33-76 yrs).
  • All patients died of tumor progression during follow-up.
  • The median overall survival from primary diagnosis of the tumor was 22 months (range, 9-133 mo).
  • CONCLUSIONS: SRS offers effective treatment as a salvage therapy for a subgroup of patients with smaller lesions of recurrent GBM.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16220556.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Chamberlain MC, Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol; 2010 Jan;96(2):259-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
  • A retrospective evaluation of single agent bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS).
  • There is no standard therapy for recurrent GBM after failure of alkylator-based chemotherapy.
  • A total of 50 adults, ages 36-70 years (median 64), with recurrent GBM were treated.
  • Time to tumor progression ranged from 0.5 to 15 months (median: 1.0 months).
  • Single agent bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator-refractory GBM.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Blood Cell Count. Creatinine / urine. Disease-Free Survival. Female. Humans. Injections, Intravenous / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593660.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; AYI8EX34EU / Creatinine
  •  go-up   go-down


69. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Histological examination confirmed recurrent pilocytic astrocytoma with organizing hematoma and granulation tissue.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Female. Granulation Tissue / pathology. Humans

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature.
  • Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors which occur almost exclusively in infants and young children.
  • There have been only 17 cases of AT/RT in adults reported in the medical literature and the rarity of this tumor makes the diagnosis in adults difficult.
  • We describe a case of an AT/RT of the spinal cord in an adult.
  • The patient underwent three additional surgical procedures for recurrent disease throughout the neuraxis secondary to leptomeningeal spread of the tumor.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. Neoplasm Recurrence, Local / pathology. Rhabdoid Tumor / pathology. Spinal Cord Neoplasms / pathology. Teratoma / pathology. Transcription Factors / genetics
  • [MeSH-minor] Adult. Cervical Vertebrae. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Monosomy / diagnosis. Monosomy / genetics

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


71. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG, New Approaches to Brain Tumor Therapy (NABTT) Consortium: Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol; 2009 Jan;91(1):51-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.
  • PURPOSE: Determining whether potentially therapeutic drug exposure is achieved within brain tumors in an exploratory clinical investigation would provide a rational basis for selecting agents for evaluation in phase II trials.
  • This study investigated the use of microdialysis to assess intratumoral drug distribution in patients with recurrent high grade gliomas (HGG).
  • Blood brain barrier (BBB) permeability of tissue in which the microdialysis probe was located was determined by digitally fusing brain CT and contrast enhanced MRI images.
  • RESULTS: The microdialysis probe was located in contrast enhancing tumor in two patients and nonenhancing tissue in two others.
  • Cerebral drug penetration, as indicated by the ratio of the area under the MTX concentration-time curves in brain extracellular fluid and plasma, was considerably greater in contrast enhancing tumor (0.28-0.31) than nonenhancing tissue (0.032-0.094).
  • Nevertheless, MTX concentrations in ECF exceeded 2-microM, the average concentration for 50% cell kill against glioma cell lines in vitro, for 20-26 h in both regions of the tumor.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2004;10(18):2145-52 [15281890.001]
  • [Cites] Curr Pharm Des. 2004;10(24):2907-21 [15379658.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Radiol Clin North Am. 1988 Jul;26(4):873-87 [3289078.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1990;51:46-8 [2128582.001]
  • [Cites] Arzneimittelforschung. 1991 Dec;41(12):1286-8 [1815530.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5451-8 [7585615.001]
  • [Cites] Pharm Res. 1995 Dec;12(12):1924-31 [8786967.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(6):499-507 [8823490.001]
  • [Cites] Int J Clin Pharmacol Ther. 1996 Aug;34(8):335-41 [8864795.001]
  • [Cites] Pharmacotherapy. 1997 May-Jun;17(3):464-81 [9165551.001]
  • [Cites] Brain Res Brain Res Rev. 1997 Sep 30;25(1):27-49 [9370049.001]
  • [Cites] Pharm Res. 1998 Jan;15(1):133-8 [9487560.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):317-24 [9516917.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Oct;42(10):2626-9 [9756766.001]
  • [Cites] Pharm Res. 1999 Aug;16(8):1219-25 [10468023.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6 [10480340.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):287-93 [15735919.001]
  • [Cites] Acta Oncol. 2005;44(4):406-11 [16120550.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] J Pharm Pharmacol. 2006 Mar;58(3):281-93 [16536894.001]
  • [Cites] Clin Pharmacokinet. 2006;45(9):871-903 [16928151.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] Br J Neurosurg. 2007 Apr;21(2):204-9 [17453790.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1909-19 [17620423.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):598-605 [17906459.001]
  • [Cites] Methods. 2001 Jan;23(1):83-94 [11162152.001]
  • [Cites] Clin Pharmacokinet. 2002;41(10):691-703 [12162757.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):794-802 [12405365.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):131-40; discussion 141-2 [14683550.001]
  • (PMID = 18787762.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / U01-CA62475; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA105689; United States / NCI NIH HHS / CA / U01 CA105689
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS575832; NLM/ PMC4029102
  •  go-up   go-down


72. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S: Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol; 2009 Apr;92(2):185-91
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival.
  • METHODS: Thirty-six patients with pathologically proven recurrent GBM were treated with salvage reirradiation by either SRS or FSRT between March of 2001 and August of 2006.
  • Of 26 patients treated with SRS, radiographic tumor response or stable disease was observed in eight (35%) patients and tumor progression was seen in 18 (65%) patients.
  • Of 10 patients treated by FSRT, radiographic tumor response or stable disease was observed in four (40%) patients and tumor progression was observed in four (40%) patients (two lost to follow-up).
  • CONCLUSION: Salvage reirradiation with SRS or FSRT for recurrent GBM results in radiographic response in a proportion of patients.
  • Further study is warranted to investigate the method and time of reirradiation for recurrent GBM.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066727.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res; 2006 Aug 15;12(16):4899-907
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Piperazines / adverse effects. Piperazines / therapeutic use. Pyrimidines / adverse effects. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Anticonvulsants / therapeutic use. Benzamides. Drug Interactions. Female. Genotype. Humans. Imatinib Mesylate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914578.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03CA102974-02
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


74. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


75. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol; 2007 Aug 1;25(22):3357-61
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
  • PURPOSE: Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma.
  • PATIENTS AND METHODS: Ninety adult patients with recurrent gliomas accrued in one center received chemotherapy with temozolomide at 150 mg/m(2)/d (days 1 through 7 and 15 through 21 every 4 weeks) with individual dose adjustments according to hematologic toxicity.
  • O(6)-methylguanine DNA methyltransferase (MGMT) gene promoter methylation in the tumor tissue was not associated with longer PFS (log-rank P = .37).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adult. DNA Methylation. Disease Progression. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Polymerase Chain Reaction. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664483.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


76. Park JW, Lee KW, Kim SJ, Choi SH, Heo JS, Kwon CH, Kim DJ, Han YS, Lee SK, Joh JW: Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation. Transplant Proc; 2006 Sep;38(7):2121-2
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation.
  • Among 156 liver transplant patients for HCC from June 1996 to February 2005, 23 had recurrent HCC.
  • The most common recurrence site was the grafted liver (n = 15), next was bone (n = 11), lung (n = 8), lymph node (n = 6), brain (n = 4), skin (n = 2), adrenal gland (n = 1).
  • There were no significant differences between the two groups in age or tumor size, number of tumors, cell differentiation, alpha-feto protein levels, tumor staging, number of patients within Milan criteria, steroid pulse therapy, infectious diseases, and immunostaining of tumor.
  • In our study, there were no risk factors that predict early tumor recurrence.
  • We noticed that more patients in the early recurrence group were excluded by Milan criteria due to a more progressed tumor staging with higher mean levels of serum alpha-feto protein.
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Neoplasm Staging. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980018.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
  • PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • CONCLUSION: In this single-institution phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients followed by chemotherapy is associated with a median survival that is greater than that of historical controls treated with surgery plus iodine-125 brachytherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy. Tenascin / immunology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down


78. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS: Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol; 2008 Oct;10(5):745-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
  • The efficacy of high-dose chemotherapy (HDC) or standard salvage therapy was evaluated in patients with recurrent medulloblastoma (MBL) using retrospective chart review of all patients with recurrent MBL treated at Duke University Medical Center between 1995 and 2005 and who had undergone HDC with or without radiotherapy (RT) or standard salvage therapy after relapse.
  • A total of 30 patients were diagnosed with recurrent MBL after standard RT alone or chemotherapy with RT.
  • All patients in groups B and C have died of tumor, at a median of 35 months and 26 months from HDC and standard salvage therapy, respectively.
  • HDC or standard salvage therapy was ineffective in our patients with recurrent MBL who had received standard RT before recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Retrospective Studies

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3720-8 [10577843.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1345-53 [18224664.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):209-18 [15050952.001]
  • [Cites] Neurology. 1986 May;36(5):597-601 [3703257.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6417-23 [3180059.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):575-82 [1885975.001]
  • [Cites] N Engl J Med. 1994 Mar 31;330(13):892-5 [8114859.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):87-98 [8699230.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1922-7 [8656261.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):222-8 [9440746.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2335-42 [16899365.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1 Suppl):5-10 [17644914.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2935-7 [10944125.001]
  • (PMID = 18755919.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2666251
  •  go-up   go-down


79. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC: Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med; 2010 May;51(5):720-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
  • METHODS: Fifteen patients with recurrent high-grade brain tumors (2 grade III, 13 grade IV) were studied at baseline (study 1 [S1]), after 1 course of therapy (2 wk, study 2 [S2]), and at the end of therapy (6 wk, study 3 [S3]). (18)F-FLT (1.5 MBq/kg) was administered intravenously, and dynamic PET was performed for 1 h.
  • Curves representing blood clearance and tumor uptake were derived from factor images and summed frames with thresholding techniques or with a fixed cube.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Brain Neoplasms / therapy. Dideoxynucleosides / pharmacokinetics. Glioma / radionuclide imaging. Glioma / therapy. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Kinetics. Male. Middle Aged. Models, Statistical. Prognosis. Survival Analysis. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395318.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; PG53R0DWDQ / alovudine
  •  go-up   go-down


80. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P, Stockhammer F, Röttgen R, Gutberlet M, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology; 2005 Jan;47(1):18-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.
  • The value of single-photon emission tomography (SPECT) using iodine-123-alpha-methyl-tyrosine (IMT) for the diagnosis of recurrent or residual gliomas is well established.
  • In the current study we investigated whether IMT-SPECT could also be useful in the follow-up of brain metastases and other intracranial tumours of non-astrocytic origin.
  • The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Iodine Radioisotopes. Methyltyrosines. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chordoma / radionuclide imaging. Ependymoma / radionuclide imaging. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging. Male. Meningioma / radionuclide imaging. Middle Aged. Neuroendocrine Tumors / radionuclide imaging. Pituitary Neoplasms / radionuclide imaging. Retrospective Studies. Rhabdoid Tumor / radionuclide imaging. Sensitivity and Specificity. Supratentorial Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630586.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 0 / Radiopharmaceuticals; 14684-02-7 / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


81. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor Consortium: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol; 2008 Apr;10(2):162-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
  • The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival (6moPFS) as the efficacy end point of therapy trials for adult patients with recurrent high-grade gliomas.
  • Progression status at 6 months is a strong predictor of survival, and 6moPFS is a valid end point for trials of therapy for recurrent malignant glioma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Stat Med. 2005 Oct 30;24(20):3155-70 [16189806.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [CommentIn] Neuro Oncol. 2008 Dec;10(6):1171-2 [18725461.001]
  • (PMID = 18356283.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 62426; United States / NCRR NIH HHS / RR / M01 RR 00042; United States / NCI NIH HHS / CA / CA 62422; United States / NCI NIH HHS / CA / U01 CA062407; United States / NCI NIH HHS / CA / U01 CA062426; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / U01 CA 62399 022030; United States / NCRR NIH HHS / RR / M01 RR 00633; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCI NIH HHS / CA / U01 CA 62405; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCRR NIH HHS / RR / M01 RR 00079; United States / NCI NIH HHS / CA / CA 62412; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCRR NIH HHS / RR / M01 RR 0865; United States / NCRR NIH HHS / RR / M01 RR 00056; United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / U01 CA 62407-08; United States / NCI NIH HHS / CA / U01 CA 62421-08; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCI NIH HHS / CA / CA 62455-08; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCRR NIH HHS / RR / M01 RR 03186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2613818
  •  go-up   go-down


82. Boiardi A, Bartolomei M, Silvani A, Eoli M, Salmaggi A, Lamperti E, Milanesi I, Botturi A, Rocca P, Bodei L, Broggi G, Paganelli G: Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol; 2005 Apr;72(2):125-31
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
  • Twenty-six recurrent Glioblastoma (rGBM) patients sequentially treated at the National Neurological Institute 'C Besta' were enrolled for a second surgery in order to remove recurrent tumor and to place an Ommaya reservoire to allow local delivery of chemotherapy and local pre-targeted radio-immunotherapy (RIT).
  • All patients had partial tumor resection and 75% of them had a residual tumor mass after exeresis larger than 2 cm.
  • We stress the concept that the combined treatments could be more effective if delivered into a smaller residual tumor mass and probably in an adjuvant setting, before tumour recurrence.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Mitoxantrone / administration & dosage. Radioimmunotherapy / methods. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Bone Marrow Diseases / chemically induced. Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Disease-Free Survival. Drug Delivery Systems / methods. Humans. Infusions, Intralesional. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Pilot Projects

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925992.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


83. Zhu JX, Li ZM, Geng FY, Fu Q, Guo CJ, Xiao YL, Zhang ZT, Li G: [Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):709-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].
  • OBJECTIVE: To evaluate the efficacy and toxicity of combination therapy with surgery and recombinant adenovirus-p53 injection of recurrent malignant gliomas.
  • METHODS: 38 patients with recurrent malignant gliomas were included in this study.
  • Among them, 18 patients of combined treatment group had Ommaya reservoirs placed into the tumor cavities after the resection of the tumors and received regular recombinant adenovirus-p53 injections after the operation.
  • CONCLUSION: The recombinant adenovirus-p53 injection is safe and effective in treatment of recurrent malignant gliomas.
  • The combination therapy of surgery and recombinant adenovirus-p53 injection may improve the life quality and the prognosis in patients with recurrent malignant gliomas.
  • [MeSH-major] Brain Neoplasms / therapy. Genetic Therapy. Glioma / therapy. Recombinant Proteins / therapeutic use. Tumor Suppressor Protein p53 / therapeutic use
  • [MeSH-minor] Adenoviridae / genetics. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Genes, p53. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122390.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


84. Ortega-Lozano SJ, del Valle-Torres DM, Gómez-Río M, Llamas-Elvira JM: Thallium-201 SPECT in brain gliomas: Quantitative assessment in differential diagnosis between tumor recurrence and radionecrosis. Clin Nucl Med; 2009 Aug;34(8):503-5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thallium-201 SPECT in brain gliomas: Quantitative assessment in differential diagnosis between tumor recurrence and radionecrosis.
  • OBJECTIVE: To compare various published thallium-201 uptake indexes in the differential diagnosis in recurrent brain gliomas.
  • MATERIAL AND METHODS: Thallium-201 SPECT studies were performed in 79 patients previously treated for glial tumor with clinical or radiologic suspicion of recurrence.
  • Regions of interest were established in the tumor area and in other sites with normal uptake.
  • Logistic regression analysis confirmed high colinearity among indexes, with index 3 (mean counts in tumor/mean counts in contralateral hemisphere) showing a slightly superior predictive power to differentiate tumor absence from tumor presence and tumor absence from low-grade recurrence.
  • CONCLUSIONS: The uptake indices studied behave similarly in the evaluation of a possible recurrence of a glial brain lesion and should be considered complementary to visual evaluation as a semi-objective tool.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Glioma / radionuclide imaging. Thallium Radioisotopes. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. ROC Curve. Recurrence. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617726.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


85. Terauchi M, Kubota T, Aso T, Maehara T: Dysembryoplastic neuroepithelial tumor in pregnancy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):730-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumor in pregnancy.
  • BACKGROUND: Dysembryoplastic neuroepithelial tumor is a rare, low-grade brain tumor that is characterized by intractable, partial seizures of juvenile onset.
  • Magnetic resonance imaging evaluation showed a 3-cm multicystic nodule in her right temporal lobe that was diagnosed, together with her history of recurrent anxiety attacks, as dysembryoplastic neuroepithelial tumor.
  • The tumor was successfully removed 2 months postpartum, and the patient has experienced no further seizures.
  • CONCLUSION: Dysembryoplastic neuroepithelial tumor was conservatively managed during pregnancy without neurosurgical intervention.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy, Multiple. Temporal Lobe. Twins
  • [MeSH-minor] Adult. Anxiety. Female. Humans. Magnetic Resonance Imaging. Male. Pregnancy. Pregnancy Outcome. Seizures


86. Bi WL, Bannykh SI, Baehring J: The growing teratoma syndrome after subtotal resection of an intracranial nongerminomatous germ cell tumor in an adult: case report. Neurosurgery; 2005;56(1):188
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growing teratoma syndrome after subtotal resection of an intracranial nongerminomatous germ cell tumor in an adult: case report.
  • OBJECTIVE AND IMPORTANCE: We report a rare complication after resection of a recurrent intracranial nongerminomatous germ cell tumor in an adult.
  • The growing teratoma syndrome, as originally described with pediatric germ cell neoplasms, represents tumor recurrence, often cystic, that sometimes is observed after partial response to multimodality therapy and despite decreasing tumor serum markers.
  • The enlarging tumor consists of elements of a mature teratoma that presumably are refractory to chemotherapy or radiation.
  • To our knowledge, this is only the third case of the growing teratoma syndrome in an adult patient with nongerminomatous germ cell tumor.
  • CLINICAL PRESENTATION: A 26-year-old man had signs of recurrent obstructive hydrocephalus 6 months after multimodality treatment of a diencephalic yolk sac tumor and endoscopic third ventriculostomy.
  • Imaging studies revealed large multilocular cystic masses originating from the tumor bed and partially obstructing the ventriculostomy.
  • INTERVENTION: Near total tumor resection and fenestration was performed.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Neoplasms, Second Primary / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Syndrome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617603.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):156-63
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
  • Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of concurrent bevacizumab with brain irradiation has not been extensively studied.
  • METHODS AND MATERIALS: After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression.
  • Three patients discontinued treatment because of Grade 3 central nervous system intratumoral hemorrhage, wound dehiscence, and bowel perforation.
  • Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma. Brain Neoplasms. Neoplasm Recurrence, Local. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy / adverse effects. Disease-Free Survival. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):646-8 [15577450.001]
  • [Cites] BMC Cancer. 2005;5:55 [15924621.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Neurosignals. 2005;14(5):207-21 [16301836.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):97-103 [16213059.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Acta Oncol. 2006;45(7):848-55 [16982549.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):723-7 [3940638.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):185-90 [17257702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90 [18234445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8 [17293237.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83 [9069310.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • (PMID = 19167838.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00595322
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS460357; NLM/ PMC3659401
  •  go-up   go-down


88. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res; 2007 Feb 15;13(4):1253-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
  • PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy.
  • This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma.
  • EXPERIMENTAL DESIGN: We conducted a phase II trial of bevacizumab and irinotecan in adults with recurrent grade III-IV glioma.
  • Patients with evidence of intracranial hemorrhage on initial brain magnetic resonance imaging were excluded.
  • No central nervous system hemorrhages occurred, but three patients developed deep venous thromboses or pulmonary emboli, and one patient had an arterial ischemic stroke.
  • CONCLUSIONS: The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2015 Oct 1;21(19):4248-50 [26429979.001]
  • [CommentIn] Curr Neurol Neurosci Rep. 2008 May;8(3):233-4 [18541118.001]
  • (PMID = 17317837.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 4 R37 CA11898; United States / NCI NIH HHS / CA / 5 P50 CA108786; United States / NINDS NIH HHS / NS / 5 P50 NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


89. Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, Iwai S, Nakazawa M, Murata I, Miyamaru H, Ono K: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S37-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies.
  • It is necessary to explore new treatments for recurrent head and neck malignancies (HNM) to avoid severe impairment of oro-facial structures and functions.
  • Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle.
  • We have treated with BNCT 42 times for 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001.
  • Results of (1) (10)B concentration of tumor/normal tissue ratios (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7. (2) Therapeutic effects were CR: 12 cases, PR: 10 cases, PD: 3 cases NE (not evaluated): 1 case.
  • Six-year survival rate was 24% by Kaplan-Meier analysis. (5) Adverse-events were transient mucositis and alopecia in most of the cases; three osteomyelitis and one brain necrosis were recognized.
  • [MeSH-major] Boron Neutron Capture Therapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Positron-Emission Tomography. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / radiotherapy. Sarcoma / mortality. Sarcoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409799.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Chamberlain MC, Glantz MJ: CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol; 2008 Sep;89(2):231-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
  • OBJECTIVE: A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS).
  • METHODS: Twenty-two patients (11 men; 11 women) ages 26-65 (median 40), with radiographically recurrent AO were enrolled.
  • Time to tumor progression ranged from 2 to 13.5 months (median: 4.5 months).
  • CONCLUSIONS: CPT-11 demonstrated modest efficacy (similar to other salvage glioma regimens) with acceptable toxicity in this cohort of adults with recurrent, 1p19q co-deleted AO all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / adverse effects. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480965.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


91. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol; 2008 Oct 1;26(28):4659-65
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
  • PURPOSE: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas.
  • Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging.
  • CONCLUSION: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92 [12604685.001]
  • [Cites] Curr Biol. 2001 Feb 20;11(4):232-41 [11250151.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1732-4 [14630677.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Nature. 1983 Jun 2-8;303(5916):390-6 [6304520.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):771-6 [9815748.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):192-201 [16890580.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4913-22 [16547494.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):432-8 [17312388.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4 [11322447.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Ann Oncol. 2002 May;13(5):777-80 [12075748.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1348-50 [12091065.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 [10850862.001]
  • (PMID = 18824712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2653126
  •  go-up   go-down


92. Abe M, Tokumaru S, Tabuchi K, Kida Y, Takagi M, Imamura J: Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg; 2006;42(2):81-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas.
  • This report documents the preliminary study results of a treatment for recurrent medulloblastomas consisting of stereotactic radiation therapy (SRT) with chemotherapy.
  • The reduction in tumor size after SRT was often remarkable.
  • In contrast, all 8 patients with metastasis had new lesions either in the spinal canal or on the surface of the brain outside the target area of SRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Medulloblastoma / therapy. Neoplasm Recurrence, Local / therapy. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Peripheral Blood Stem Cell Transplantation. Radiotherapy Dosage. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16465076.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


93. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


94. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol; 2009 Oct 1;27(28):4733-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
  • PURPOSE: We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
  • CONCLUSION: Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Drug Administration Schedule. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Young Adult


95. Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg; 2006 Dec;105(6):898-903
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for recurrent malignant meningioma. Case report.
  • Malignant meningioma is a rare brain tumor with a high risk of recurrence.
  • If this tumor recurs after complete resection and adjuvant radiotherapy, there is no optimal treatment to control it.
  • The authors report the first case of recurrent malignant meningioma treated using boron neutron capture therapy (BNCT).
  • This 25-year-old pregnant woman presented with a large frontal tumor.
  • After her baby was born, she underwent gross-total resection of the tumor.
  • The minimum tumor dose and maximum brain tissue dose were estimated as 39.7 Gy-Eq and less than 9.0 Gy-Eq, respectively.
  • Twenty-two weeks later she underwent a second BNCT for tumor regrowth on the contralateral side, and the lesion was subsequently reduced.
  • The tumor volume was markedly decreased from 65.6 cm3 at the time of the first BNCT to 31.8 cm3 at 26 weeks thereafter.
  • The treatment of recurrent malignant meningioma is difficult and has been discouraging thus far.
  • Data in the present case indicate that BNCT may be a promising treatment option for this challenging tumor.
  • [MeSH-major] Boron Neutron Capture Therapy. Cranial Irradiation. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pregnancy Complications, Neoplastic / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neurologic Examination. Positron-Emission Tomography. Pregnancy. Radiosurgery. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405262.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Kyrgiannis K, Mourgela S, Karamanakos PN, Liaropoulos K, Papadakis N: Optimal treatment of a recurrent giant craniopharyngioma: lessons from a case. J BUON; 2008 Oct-Dec;13(4):593-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal treatment of a recurrent giant craniopharyngioma: lessons from a case.
  • The tumor had grown enormously in dimensions and was extending in the region of hypothalamus, third ventricle and brain stem, with signs of local compression and obstructive hydrocephalus.
  • We conclude that in expert hands, microsurgery aiming at total removal should be the therapeutic option for the treatment of recurrent as well as primary craniopharyngiomas.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145689.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. Xu JL, Li YL, Lian JM, Dou SW, Yan FS, Wu H, Shi DP: Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging. Neuroradiology; 2010 Dec;52(12):1193-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
  • INTRODUCTION: This study aims to evaluate the differentiated effectiveness of MR diffusion tensor imaging (DTI) to postoperative recurrent glioma and radiation injury.
  • METHODS: Conventional MRI and DTI examination were performed using Siemens 3.0 T MR System for patients with new contrast-enhancing lesions at the site of treated tumor with postoperative radiotherapy.
  • Twenty patients with recurrent tumor and 15 with radiation injury were confirmed by histopathologic examination (23 patients) and clinical imaging follow-up (12 patients), respectively.
  • RESULTS: The mean ADC ratio at contrast-enhancing lesion area was significantly lower in patients with recurrent tumor (1.34 ± 0.15) compared to that with radiation injury (1.62 ± 0.17; P < 0.01).
  • The mean FA ratio at contrast-enhancing lesion area was significantly higher in patients with recurrent tumor (0.45 ± 0.03) compared to that with radiation injury (0.32 ± 0.03; P < 0.01).
  • A recurrent tumor was suggested when either ADC ratio <1.65 or/and FA ratio >0.36 at contrast-enhancing lesion area according to the receiver operating characteristics curve analysis.
  • Three patients with recurrent tumor and two with radiation injury were misclassified.
  • CONCLUSION: DTI is a valuable method to distinguish postoperative recurrent glioma and radiation injury.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging / methods. Female. Humans. Male. Middle Aged. Postoperative Care. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571787.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer S, Junck L: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol; 2005 Dec;185(6):1471-6
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy.
  • OBJECTIVE: The purpose of our study was to explore the feasibility and utility of 2D chemical shift imaging (CSI) MR spectroscopy in the evaluation of new areas of contrast enhancement at the site of a previously treated brain neoplasm.
  • MATERIALS AND METHODS: Two-dimensional CSI (point-resolved spectroscopy sequence [PRESS]; TR/TE, 1,500/144) was performed in 29 consecutive patients (4-54 years old; mean age, 34 years) who had a new contrast-enhancing lesion in the vicinity of a previously diagnosed and treated brain neoplasm.
  • The Cho/Cr (choline/creatine) and Cho/NAA (choline/N-acetyl aspartate) ratios were significantly higher, and the NAA/Cr ratios significantly lower, in tumor than in radiation injury (all three differences, p < 0.0001).
  • Mean Cho/Cr ratios were 2.52 for tumor, 1.57 for radiation injury, and 1.14 for normal-appearing white matter.
  • When values greater than 1.8 for either Cho/Cr or Cho/NAA ratios were considered evidence of tumor, 27 of 28 patients could be correctly classified.
  • CONCLUSION: Two-dimensional CSI MR spectroscopy can differentiate tumor from radiation injury in patients with recurrent contrast-enhancing intracranial lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods. Neoplasm Recurrence, Local / diagnosis. Radiation Injuries / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Child. Child, Preschool. Choline / metabolism. Contrast Media. Creatine / metabolism. Diagnosis, Differential. Feasibility Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304000.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


99. Secondino S, Citterio A, Pedrazzoli P, Funaioli C, Scialfa GG, Siena S: Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. Anticancer Res; 2008 Nov-Dec;28(6B):3991-2
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
  • We report on radiological abnormalities resembling recurrent tumor in adult medulloblastoma receiving intensified chemotherapy and radiotherapy.
  • Evidence provided in this paper confirms previous reports in the pediatric population and suggests that neuroradiologist and medical oncologists should be aware of new possible radiological findings related to aggressive treatments for brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192661.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


100. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol; 2010 Aug 20;28(24):3838-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scale to predict survival after surgery for recurrent glioblastoma multiforme.
  • In this study, we sought to devise a preoperative scale that predicts survival after surgery for recurrent glioblastoma multiforme.
  • PATIENTS AND METHODS: The preoperative clinical and radiographic data of 34 patients who underwent re-operation of recurrent GBM tumors were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling.
  • RESULTS: The factors associated with poor postoperative survival were: tumor involvement of prespecified eloquent/critical brain regions (P = .021), Karnofsky performance status (KPS) < or = 80 (P = .030), and tumor volume > or = 50 cm(3) (P = .048).
  • CONCLUSION: We devised and validated a preoperative scale that identifies patients likely to have poor, intermediate, and good relative outcomes after surgical resection of a recurrent GBM tumor.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Pharmacol Ther. 2010 Oct;128(1):1-36 [20546782.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):607-14 [2827051.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):817-24 [18976070.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] N Engl J Med. 2010 Jan 21;362(3):e6 [20054035.001]
  • [CommentIn] J Clin Oncol. 2011 Feb 1;29(4):e102; author reply e103 [21172889.001]
  • (PMID = 20644085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940401
  •  go-up   go-down






Advertisement